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Abstract 
The discovery of the genetic causes of syndromic autism spectrum disorders and 
intellectual disabilities has greatly informed our understanding of the molecular pathways 
critical for normal synaptic function. The top-down approaches using human phenotypes 
and genetics helped identify causative genes and uncovered the broad spectrum of 
neuropsychiatric features that can result from various mutations in the same gene. 
Importantly, the human studies unveiled the exquisite sensitivity of cognitive function to 
precise levels of many diverse proteins. Bottom-up approaches applying molecular, 
biochemical, and neurophysiological studies to genetic models of these disorders 
revealed unsuspected pathogenic mechanisms and identified potential therapeutic targets. 
Moreover, studies in model organisms showed that symptoms of these devastating 
disorders can be reversed, which brings hope that affected individuals might benefit from 
interventions even after symptoms set in. Scientists predict that insights gained from 
studying these rare syndromic disorders will have an impact on the more common 
nonsyndromic autism and mild cognitive deficits.  
It is estimated that ∼1% of the human population has an autism spectrum disorder (ASD). 
ASD has widely varied behavioral manifestations, severity, and comorbid conditions 
(hence the term “spectrum”), but those diagnosed with autism are characterized by 
impaired communication and reciprocal social interactions, and restricted and repetitive 
patterns of activities and interests (Baird et al. 2006). Approximately 70% of those 
diagnosed with autism also have intellectual disability (ID), and 25% have a seizure 
disorder (Tuchman and Rapin 2002). There is a strong genetic basis for autism, but the 
risk architecture is highly heterogeneous, and a large number of genes have been 
implicated (Abrahams and Geschwind 2008). This daunting phenotypic and etiologic 
complexity, shared by other major psychiatric illnesses, has slowed progress toward 
developing new therapies.  
However, autism researchers are optimistic that the possibility of substantial progress 
may soon be realized (Krueger and Bear 2011). First, the genes have been discovered for 
numerous syndromic disorders that prominently feature ASD and ID. Second, these gene 
mutations have been reproduced in animal models that allow detailed examination of the 
underlying brain pathophysiology. Third, animal research has converged on altered 
synaptic function as a likely basis for impaired cognition and possibly ASD. Fourth, 
insights gained on how synapses function differently in the face of these mutations have 
suggested novel therapeutic interventions validated in preclinical models and that have 
shown promise in preliminary human clinical trials. Fifth, the fact that ASD and ID can 
be diagnosed in early childhood maximizes potential benefits of therapy because it can be 
started at a time when the brain is most plastic. Finally, animal studies using gene 
reactivation or pharmacological interventions suggest that substantial improvements can 
be seen even when treatments begin in adulthood (Ehninger et al. 2008b). Thus, a genetic 
diagnosis of a developmental brain disorder need not be a “life sentence” of permanent 
and inexorable mental disability.  
The path from gene discovery to novel treatment is outlined in Figure 1. This process 
often begins with astute clinical observations that some patients can be distinguished by a 
common set of phenotypic traits, thus defining a syndrome. Molecular genetic studies can 
then be undertaken to test the hypothesis that the syndrome has a genetic cause. In the 
event that disruption of a single gene or DNA segment causes the disease (i.e., a “highly 
penetrant” mutation), then it is possible to create an animal model (usually a mouse) that 
carries the same genetic disruption. Although the effects of the genetic lesion will likely 
manifest differently at the behavioral level in animals and humans because of differences 
in the complexity of the brains, it is reasonable to postulate that disruptions in elementary 
neuronal functions are likely to be shared. Understanding this neuronal pathophysiology 
is critical for identifying potential therapeutic targets. If these targets can be validated in 
the animal models, then chemistry ensues to generate molecules that can engage the 
target and satisfy the pharmacodynamic and pharmacokinetic drug requirements. If they 
are shown to be safe, drug candidates may then advance to human clinical trials. There 
are currently clinical trials ongoing in several single-gene syndromic disorders associated 
with ASD and ID. Most of these target alterations in synaptic signaling.  
Figure 1. The promise of molecular medicine in genetically defined disorders of brain development. 
The notion that some ASD and associated ID represent “synapsopathies” (or 
“synaptopathies”) is supported by the preponderance of penetrant mutations in genes 
associated with synaptic structure and function. The most common single-gene mutations 
in ASD with ID are associated with fragile X syndrome (FMR1), tuberous sclerosis 
(TSC1, TSC2), neurofibromatosis (NF1), Angelman syndrome (UBE3A), Rett syndrome 
(MECP2), the PTEN hamartoma tumor syndrome, and Phelan-McDermid syndrome 
(SHANK3) (for review, see Betancur 2011). Rare mutations in the neuroligin (NLGN3, 
NLGN2) and neurexin (NRXN1) genes also cause autism (Jamain et al. 2003). Although 
this is by no means an exhaustive list of genes implicated in autism (and many await 
discovery), it is notable nonetheless that these highly penetrant mutations occur in genes 
that are critical regulators of synaptic function, and further, illuminate biochemical 
pathways that might be pathogenic in ASD and ID (Fig. 2).  
Figure 2. (A) Schematic of a neuron and axonal-dendritic synapse that depict examples of cellular 
localization of the various types of defects in ASD/ID. (B) A signaling pathway at the excitatory 
synapses that couples activity as registered by the release of glutamate to local control of protein 
synthesis. Disruption of the gene products indicated in the colored boxes greatly increases the risk of 
ASD/ID. Syndromic disorders with increased prevalence of ASD include Phelan-McDermid Syndrome 
(SHANK3); Noonan syndrome (RAF1, MEK1); Neurofibromatosis type 1 (NF1); Costello syndrome 
(H-Ras, MEK1); Cowden syndrome (PTEN); Cardio-facio-cutaneous (CFC) syndrome (MEK1/2); 
Tuberous sclerosis complex (TSC1/2); Fragile X syndrome (FMRP); Angelman syndrome (AS 
UBE3a); Rett syndrome (RTT–MeCP2); and Rubinstein-Taybi syndrome (RTS–CREB binding protein, 
p300). Rare, nonsyndromic ASDs include NLGN3/4 and NRXN1; ID/ASD: SHANK2.  
In this article, we focus on a few syndromic disorders associated with ASD and ID that 
are characterized by penetrant mutations in genes that have been shown in animal models 
to disrupt synaptic function. Our goal is to highlight the similarities and differences in 
these syndromes and their underlying synaptic pathophysiology. Optimal synaptic 
function occurs within a narrow dynamic range along many dimensions, and it is not 
surprising that pathophysiology occurs at the edges of these spectra. What has come as a 
surprise, however, is that ASD and ID appear to be common consequences of disruptive 
mutations that cause synaptic pathophysiology at both ends of a spectrum. In other 
words, both “gain-of-function” and “loss-of-function” mutations can manifest in similar 
ways. Insights into the pathophysiology of ASD and ID have raised the possibility of 
therapeutic interventions to bring synapses into a normal operating range.  
SINGLE GENE DISORDERS OF SYNAPTIC SCAFFOLDING AND 
STRUCTURE 
Phelan-McDermid Syndrome and SHANK3 Disorders  
Clinical Features and Phenotypic Spectrum 
Phelan-McDermid syndrome (PMS) is a microdeletion syndrome of chromosome 22q13 
characterized by severe neonatal hypotonia, some dysmorphic features, and global 
developmental delay. Patients have severe language delay or no speech; they have poor 
eye contact, decreased socialization, and stereotyped movements. Additional neurological 
phenotypes include teeth grinding, aggressive behavior, and seizures (Phelan et al. 2001; 
Phelan 2008; Dhar et al. 2010).  
PMS results from deletions of variable length at the terminal region of the long arm of 
chromosome 22. Studies aimed at identifying the gene(s) critical for PMS phenotypes led 
to the identification of SH3 and Ankyrin-domain-containing protein (SHANK3) as the 
gene responsible for many neurological phenotypes. Bonaglia et al. (2001) were the first 
to identify disruption in SHANK3 (also known as ProSAP2) in an affected child with a 
translocation. Characterization of DNA from more than 60 additional patients revealed 
consistently that heterozygous loss of SHANK3 is responsible for the neurological 
phenotypes (Anderlid et al. 2002; Wilson et al. 2003; Dhar et al. 2010). The discovery 
that PMS is caused by haploinsufficiency of SHANK3 inspired investigators to evaluate 
this gene in other disorders, especially ASDs. Deletions spanning SHANK3 as well as 
protein-truncating mutations were discovered in patients with autism and ID (Durand et 
al. 2007; Moessner et al. 2007). Furthermore, duplications spanning SHANK3 have also 
been reported in a patient with Asperger and in two patients with ID and dysmorphic 
features (Durand et al. 2007; Okamoto et al. 2007). Recently, de novo mutations in 
SHANK3 were identified in patients with schizophrenia (Gauthier et al. 2010). 
Altogether, these data show that the phenotypes caused either by haploinsufficiency or 
duplication of SHANK3 include PMS, ASD with cognitive deficits, ID, and 
schizophrenia.  
Pathophysiology 
Biochemical and in vivo genetic studies are providing insight into the function of Shank3 
and its paralogs. The Shank protein family, which includes Shank1, 2, and 3, are 
components of the postsynaptic density and interact with guanylate kinase–associated 
protein (also known as PSD-95-binding protein or SAPAP), Homer, cortactin-binding 
protein, and the somatostatin receptor (Du et al. 1998; Boeckers et al. 1999; Naisbitt et al. 
1999; Tu et al. 1999; Yao et al. 1999; Zitzer et al. 1999). Shank proteins, also known as 
proline-rich synapse-associated proteins (ProSAPs), contain several protein–protein 
interaction domains. The amino termini contain five to six ankyrin repeats, followed by 
the Src homology 3 (SH3) domain and the PDZ domain. The carboxyl terminus contains 
several proline-rich clusters, a cortactin-binding domain, and a sterile α motif. Alternative 
splicing and alternative transcription start sites, as well as internal promoter regulation, 
result in Shank isoforms that lack another domain (Boeckers et al. 1999; Lim et al. 1999; 
Maunakea et al. 2010). All Shank proteins are expressed in the brain, especially in 
cortical and hippocampal neurons; however, the expression of different paralogs varies in 
other brain regions and tissues (Lim et al. 1999). Shank proteins localize to the PSD and 
stabilize PDS-95/SAPAP/Shank/Homer complexes. In addition, they recruit inositol 1, 4, 
5-triphosphate (IP3) receptors and F-actin to the synapse, thereby enlarging dendritic 
spine heads and stabilizing them (Tu et al. 1998, 1999; Sala et al. 2001). Consistent with 
the important role of Shank proteins in synaptic function, overexpression of Shank1 in 
hippocampal neurons leads to increased maturation and size of dendritic spines (Sala et 
al. 2001). Furthermore, deletion of Shank1 in mice leads to smaller spines, thinner PSDs, 
and weakened synaptic transmission. Shank1-null mice displayed anxiety-like behavior, 
impaired contextual fear memory, and poor long-term retention of a spatial task despite 
the enhanced performance on this task (Hung et al. 2008).  
In vitro and in vivo studies highlight the important role of Shank3 for synaptic function. 
Knockdown of Shank3 in hippocampal neurons cultured in vitro leads to reduced number 
and increased length of dendritic spines, whereas expression of Shank3 in aspiny 
cerebellar granule neurons is sufficient to induce functional dendritic spines (Roussignol 
et al. 2005). Two recent studies reported on the in vivo consequences of loss of Shank3 
function in mice. Bozdagi et al. 2010 deleted the exons coding for the ankyrin repeat 
domain; thus, the mice lacked the full-length, long isoform of Shank3. Shank3+/− mice 
lacking the long isoform had reduced basal synaptic transmission in hippocampal CA1 
neurons and decreased long-term potentiation (LTP). The finding of decreased GluR1-
positive puncta in the stratum radiatum suggests altered AMPA receptor trafficking 
(Bozdagi et al. 2010). In addition to these synaptic abnormalities, Shank3+/− males 
displayed reduced responses to female social cues but no deficits on additional social 
tasks (Bozdagi et al. 2010). Two additional Shank3 mutant mice have been characterized: 
one termed Shank3A in which the long isoform (Shank3α) is ablated by deletion of the 
ankyrin repeats, and a second termed Shank3B in which the PDZ domain is targeted, thus 
eliminating both the long α isoform and short Shank3β isoform (Peça et al. 2011). 
Shank3B−/− mice, in particular, groomed excessively, displayed anxiety-like behaviors, 
and showed decreased social interactions. Analysis of striatal synaptic extracts from 
Shank3B−/− mice revealed decreased levels of several PSD proteins including SAPAP3, 
Homer, PSD-93, GluR2, NR2A, and NR2B. In addition to the biochemical changes, the 
thickness and length of the PSD were reduced, and there was a significant reduction of 
spine density. Finally, these postsynaptic changes accompanied reduced excitatory 
synaptic transmission in the striatum (Peça et al. 2011). Although Shank3B+/− mutants 
need to be studied further to relate the behavioral, synaptic, and biochemical changes to 
the PMS, the findings from both the Shank3+/− and Shank3B−/− mice point to disruption of 
glutamatergic signaling and AMPA-mediated transmission in both models and raise the 
possibility that enhancement of AMPA transmission might be helpful in disorders 
resulting from haploinsufficiency of SHANK3.  
Disorders Due to Dysfunction of Neuroligins and Neurexins 
Clinical Features and Phenotypic Spectrum 
Mutations in the X-linked NEUROLIGIN3 and NEUROLIGIN4 (NLGN3 and NLGN4) 
were among the first ASD-causing mutations to be identified. A missense mutation 
causing R451C substitution within a highly conserved region in NLGN3 was detected in 
two male siblings: one with autism, severe intellectual disability, and seizures; and his 
brother with Asperger syndrome. Their mother, a carrier, did not manifest any 
phenotypes, which is typical of many X-linked disorders (Jamain et al. 2003). The 
mutations in NLGN4 cause a frameshift and early truncation of the protein. The first 
identified NLGN4 mutation occurred in a male with autism, in his brother with Asperger 
syndrome, and in the asymptomatic carrier mother (Jamain et al. 2003). Other truncating 
mutations were identified in all affected members of a large family with X-linked ID 
(Laumonnier et al. 2004) and in two male siblings; one with autism, ID, and a motor tic, 
and another with attention deficit hyperactivity, cognitive deficits, and Tourette syndrome 
diagnosis (Lawson-Yuen et al. 2008).  
A de novo single-base substitution near the promoter region of NLGN4 has been reported 
in one male with autism and profound ID. The investigators suspect that this mutation 
leads to increased NLGN4 mRNA levels (at least in lymphoblast lines), raising the 
possibility that NLGN4 overexpression is also detrimental (Daoud et al. 2009). Thus, 
mutations in NLGN3 and NLGN4 cause a wide range of social and cognitive 
abnormalities ranging from Asperger autism to severe cognitive deficits and tics. These 
discoveries inspired studies to determine if NLGN receptors and neurexins are mutated in 
ASD. The first abnormalities involving NEUREXIN1 (NRXN1) were identified in two 
individuals with ASD and balanced chromosomal abnormalities (Kim et al. 2008). 
Subsequently, another abnormality was detected in a boy with dysmorphic features, 
cognitive deficits, and autistic features who had a large deletion that included the part of 
NRXN1 that codes for the α-promoter and exons 1–5, leaving the downstream β-promoter 
intact (Zahir et al. 2008). Compound heterozygosity for deletion and stop mutations 
(S979X) in NRXN1 have been reported in a patient with autistic behaviors, severe ID, 
hyperbreathing, and some dysmorphic features (Zweier et al. 2009).  
Several deletions and duplications of NRXN1 have been reported in patients with 
schizophrenia. Although some copy number variants (CNVs) were reported in controls, 
their higher prevalence in schizophrenia and ASD/ID, as well as occasional truncating 
mutations in NRXN1, suggest that haploinsufficiency of NRXN1 confers a risk of ID, 
ASD, or schizophrenia (Rujescu et al. 2009; Ching et al. 2010; Gauthier et al. 2011). A 
single frameshifting mutation in NRXN2 has been reported in a patient with ASD and in 
his father, who has language delay (Gauthier et al. 2011).  
Pathophysiology 
NRXNs and NLGNs are synaptic cell adhesion molecules whose critical role in synaptic 
function has been well established. Three genes—NRXN1, NRXN2, and NRXN3—encode 
for mammalian NRXNs, each generating two isoforms, α and β, from independent 
promoters. The α-isoform is longer and contains six extracellular Laminin, NRXN, sex-
hormone binding globulin domains (LNS) and three epidermal growth factor-like 
domains, whereas the β-isoform contains a single LNS domain (Tabuchi and Sudhof 
2002). Complex alternative splicing generates thousands of splice variants (Missler and 
Sudhof 1998). NLGNs are endogenous ligands for NRXN and are encoded by four genes 
in humans: NLGN 1, 2, 3, and 4. They undergo alternative splicing at one (NLGN2, 3, and 
4) or two (NLGN1) sites. Both NRXNs and NLGNs have single transmembrane domains 
and short cytoplasmic domains containing PDZ-binding motifs at the carboxyl terminus 
(Hata et al. 1996; Irie et al. 1997). NRXNs and NLGNs form a trans-synaptic complex 
believed to organize the presynaptic and postsynaptic compartments through various 
interactions with proteins like CASK, MAGUK, and PSD95 (Sudhof 2008). Although 
evidence about the functional roles of NLGNs and NRXNs initially came from 
coculturing experiments showing that expression of these proteins in nonneuronal cells 
can induce presynaptic and postsynaptic specialization, respectively (Scheiffele et al. 
2000; Graf et al. 2004; Nam and Chen 2005), genetic studies in mice underscored the 
importance of these molecules for synaptic function. Mice lacking Nlgn1, 2, and 3 have 
normal synapse numbers and ultrastructure, but die perinatally from respiratory failure. 
Neurophysiological studies revealed that glutamatergic and GABAergic/glycinergic 
synaptic transmission is impaired in the respiratory centers of the triple null animals 
(Varoqueaux et al. 2006). Interestingly, mice carrying a single deletion or double 
knockout of these genes are viable. The finding that Nlgn1 deficiency impairs N-methyl-
d-aspartate (NMDA) receptor signaling, whereas Nlgn2 deficiency causes deficits in 
inhibitory synaptic transmission, is consistent with the localization of NLGN1 and 2 to 
excitatory and inhibitory synapses, respectively (Chubykin et al. 2007). The data also 
argue that the lethality of the triple null animals is due to synthetic effects rather than 
functional redundancy. Loss of NLGN 3 causes some features that are typically seen in 
ASD patients. Nlgn3-null mice displayed impaired ultrasound vocalization and altered 
social memory, possibly owing to olfactory deficiency. The animals, however, performed 
as well as wild types on direct social interactions and did not have learning deficits or 
stereotypies (Radyushkin et al. 2009).  
Mice carrying a knockin allele with the R451C substitution (discovered in a single ASD 
patient) displayed impaired social interactions, enhanced spatial learning, and had 
increased levels of vesicular inhibitory amino acid transporter without evidence of an 
increased number of synapses. In addition, the R451C knockin mice had increased 
inhibitory synaptic transmission. In contrast, the Nlgn3-null mice did not manifest such 
changes, supporting the proposal that the R451C substitution causes behavioral and 
neurophysiological phenotypes by a gain-of-function mechanism (Tabuchi et al. 2007). A 
deletion of an NLGN4 ortholog in mice caused impaired social interactions and decreased 
ultrasonic vocalization, consistent with the human studies illustrating that loss-of-
function mutations cause ASD and ID (Jamain et al. 2008).  
Studies of mice lacking NRXNs are complicated by the existence of various isoforms. 
Mice lacking α-NRXN isoforms through targeting of the α-isoforms in all three Neurexin 
genes (Nrxn1, 2, and 3) die prenatally because of breathing difficulties. The individual 
Nrxn knockout mice live longer but are also compromised and die at different times 
postnatally. Synapse numbers (except for minor decline in inhibitory synapse number) 
and ultrastructural studies did not reveal major abnormalities. Synaptic function, 
however, was impaired, as evident by decreased spontaneous as well as evoked 
neurotransmitter release in both the neocortex and the brain stem of α-NRXN-deficient 
mice. Presynaptic Ca2+ channel function was compromised in the α-NRXN-null mice 
based on decreased presynaptic Ca2+ currents, especially N-type Ca2+ currents (Missler et 
al. 2003).  
These data illustrate that the α-NRXNs, like their ligands the NLGNs, are essential for 
proper synapse assembly and function, but not for the initial formation of synapses. 
Exactly how haploinsufficiency of NRXN1 causes the ASD/ID and schizophrenia 
spectrum phenotypes must await additional studies, but it is certain to involve some 
synaptic dysfunction.  
SINGLE-GENE DISORDERS OF SYNAPTIC SIGNALING 
Fragile X Syndrome 
Clinical Features and Phenotypic Spectrum 
In 1943, Martin and Bell described a family in which intellectual deficits (then reported 
as mental retardation) segregated as an X-linked trait (Martin and Bell 1943). Lubs 
subsequently observed a constriction on the long arm of the X chromosome in some 
males with ID. Moreover, Lubs reported that the affected males had macroorchidism 
(large testes); large, low-set ears; asymmetric facial features, and large hands (Lubs 1969; 
von Reyn et al. 1978). After mapping of this chromosomal variation to Xq27.3 (Harrison 
et al. 1983) and confirming the fragile site in many families segregating ID, the disorder 
became known as fragile X syndrome (FXS). Affected males have moderate to severe ID, 
speech delay, and motor abnormalities. Common psychiatric features include 
hyperactivity, anxiety, and severe autism spectrum phenotypes. Many males with FXS 
display gaze avoidance and stereotyped repetitive behaviors, and insist on sameness. 
Connective tissue abnormalities are common and include joint hyperextensibility, mitral 
valve prolapse, and mild dilation of the aorta (Hagerman et al. 1984). About one-third of 
the females with FXS have some ID.  
Postmortem neuropathological studies revealed structural abnormalities of dendritic 
spines (Comery et al. 1997; Irwin et al. 2000). Specifically, there is an increase in spine-
like protrusions on apical and basal dendrites in fragile X cerebral cortex, raising the 
possibility of failure of the normal spine elimination that typically occurs during postnatal 
development. Since the discovery that expansions of a CGG repeat in the fragile X 
mental retardation gene (FMR1) causes FXS (Fu et al. 1991; Verkerk et al. 1991), 
additional phenotypes were uncovered in premutation carriers. Specifically, males (and, 
to a lesser degree, females) carrying premutation alleles developed a late-onset 
neurodegenerative disorder known as fragile X–associated tremor/ataxias syndrome 
(FXTAS) (Hagerman and Hagerman 2004). About 25% of females carrying a 
premutation allele develop premature ovarian failure (Allingham-Hawkins et al. 1999).  
Pathophysiology 
The protein product of the FMR1 gene, called FMRP (fragile X mental retardation 
protein), is enriched in neurons and binds to mRNAs both in the soma and the dendrites. 
Several functional roles have been proposed, but the evidence is now quite compelling 
that FMRP serves as a negative regulator of translation of many mRNA transcripts 
(O’Donnell and Warren 2002). Mouse and fly fragile X models, in which the genes 
homologous to FMR1 have been knocked out, have been instrumental in understanding 
the pathophysiology of the disease (Bhogal and Jongens 2010). Consistent with the 
notion of FMRP as a translational repressor, an increased rate of basal protein synthesis is 
observed in the hippocampus of Fmr1-null mice (Qin et al. 2005; Osterweil et al. 2010).  
Important synaptic regulators of protein synthesis are metabotropic glutamate receptors 1 
and 5 (mGluR1 and mGluR5) (Greenough et al. 2001). These receptors appear to be part 
of a molecular machine that ensures that the supply of synaptic proteins keeps up with 
demand as registered by the release of glutamate at excitatory synapses. Partial inhibition 
of mGluR5 can restore wild-type levels of protein synthesis in the Fmr1-null mice 
(Aschrafi et al. 2005; Dolen et al. 2007; Gross et al. 2010; Osterweil et al. 2010). The 
theory that excessive protein synthesis downstream from mGluR5 is pathogenic in fragile 
X (Bear et al. 2004) has now been extensively tested and validated in both mouse and fly 
models (Krueger and Bear 2011). Based on the strength of these preclinical findings, 
negative mGluR5 regulators recently entered human clinical trials for fragile X syndrome 
(Levenga et al. 2010). Preliminary results appear promising, and larger trials are planned 
(Jacquemont et al. 2011). Additional exploratory trials are being conducted using 
minocycline, an inhibitor of the matrix metalloproteinase MMP-9, which is regulated by 
mGluR5 and FMRP and is overexpressed in the Fmr1-null mouse (Bilousova et al. 2009; 
Wang et al. 2010).  
Another consistent finding in animal models of fragile X is evidence for impaired 
GABAergic inhibition (Levenga et al. 2010). This impairment could be a consequence of 
excessive protein synthesis during development or a parallel pathophysiologic process. In 
any case, some fragile X phenotypes that respond to mGluR5 inhibitors have also been 
ameliorated by administering compounds that activate GABA receptors, both in the 
mouse (Pacey et al. 2009; Olmos-Serrano et al. 2010) and the fly (Chang et al. 2008) 
models. The selective GABAB receptor agonist R-baclofen has recently attracted interest 
as a potential therapeutic in FXS, because it both decreases neuronal excitability via 
activation of dendritic potassium conductances and directly inhibits the synaptic release 
of glutamate (and therefore, indirectly, mGluR5 activation) (Kohl and Paulsen 2010).  
Angelman Syndrome 
Clinical Features and Phenotypic Spectrum 
Angelman syndrome (AS) is characterized by intellectual and developmental disabilities, 
balance problems, severe language deficits, and seizures. These children display various 
behavioral problems, including hand-flapping movements that led Angelman to describe 
them as “puppet children” (Angelman 1965). Bower and Jeavons described the syndrome 
as “happy puppet syndrome” because of the happy disposition, frequent smiles, and 
unexplained bouts of laughter (Bower and Jeavons 1967). Additional features include 
hyperactivity, sleep abnormalities, tongue protrusion, and some dysmorphic features like 
a prominent mandible and wide mouth (Clayton-Smith 1993). Pathologically, the only 
consistent deficit is the small brain size. The majority of AS cases are caused by maternal 
deletions of 15q11-q13, whereas 2%–5% result from paternal uniparental disomy of 
15q11-13. Imprinting defects involving the bipartite imprinting center in 15q11-13 also 
account for some cases of AS (Magenis et al. 1987; Nicholls et al. 1989; Ohta et al. 
1999). The culprit gene in 15q11-13 is the ubiquitin E3 ligase (UBE3A) (Kishino et al. 
1997; Matsuura et al. 1997).  
Pathophysiology 
Several synaptic deficits were described in the Ube3a knockout mouse model of AS 
(Philpot et al. 2010), including reduced density and strength of excitatory synapses and, 
at later developmental stages, reduced functional inhibition. Striking synaptic plasticity 
phenotypes include a severe impairment in NMDA receptor-dependent long-term 
depression (LTD), an increased threshold for long-term potentiation (LTP), and a loss of 
experience-dependent visual cortical plasticity (Yashiro et al. 2009; Sato and Stryker 
2010). This synaptic rigidity will likely account for ID in AS.  
Because Ube3a directs proteolysis via the proteasome, the deficits in synaptic function 
and plasticity are believed to be related to increased levels of Ube3a target proteins. 
Although there are many potential targets, the search is narrowed by the important 
discovery that the pathogenic proteins appear to be regulated by neural activity (Yashiro 
et al. 2009). Reducing visual cortical activity by housing the mice in complete darkness 
restored normal LTD and LTP in the Ube3a-null mice. One activity-regulated protein 
that is rapidly reduced in visual cortex by dark exposure is Arc, critical for glutamate 
receptor trafficking at synapses (Shepherd and Bear 2011). Recent work has shown that 
Arc is a Ube3a substrate and is overexpressed in the null mice. Increased expression of 
Arc in the absence of Ube3a leads to internalization of AMPA receptors and impaired 
excitatory synaptic transmission (Greer et al. 2010). Arc is translated downstream from 
activation of mGluR5 and regulated by FMRP. Thus, excessive or poorly regulated 
expression of Arc could be a convergence point in the pathophysiology of FXS and AS 
(Kelleher and Bear 2008). It is of great interest to know if inhibitors of mGluR5 correct 
mutant phenotypes in the Angelman mouse model.  
Another important observation is that boosting the activity of αCaMKII (calcium-
calmodulin-dependent protein kinase II) by mutating an inhibitory phosphorylation site 
can rescue LTP and learning deficits in the Ube3a mutant mice (van Woerden et al. 
2007). Increased expression (Neve and Bear 1989) and recruitment of αCaMKII to 
synapses via the NR2B subunit of NMDA receptors in the visual cortex (Chen and Bear 
2007) are known consequences of dark exposure. Thus, strategies to increase 
phosphorylation of αCaMKII substrates (which include AMPA receptors) may represent 
another therapeutic approach to AS.  
It is noteworthy that maternal duplication of the 15q11-q13 region occurs in ∼1% of 
individuals with nonsyndromic autism (Cook et al. 1998; Christian et al. 2008). 
Overexpression of UBE3A and consequent reductions in ARC could contribute to the 
pathophysiology, because an Arc knockout mouse shows impairments in synaptic 
plasticity that are similar to those reported in the Ube3a-null mice (McCurry et al. 2010). 
Regardless of the cause, duplications and deletions of 15q11-q13 provide another 
example of how ASD and ID (and defective synaptic plasticity) can be a common 
consequence of both increased and decreased gene dosage.  
Tuberous Sclerosis Complex 
Clinical Features and Phenotypic Spectrum 
Tuberous sclerosis complex (TSC) is a neurocutaneous dominantly inherited multisystem 
disorder characterized by the presence of benign tumors (hamartomas) that occur in many 
organs, but most notably the brain, skin, eyes, kidneys, and heart (Curatolo et al. 2008). 
These hamartomas represent overgrown cells from the tissue within which they reside. 
Friedrich von Recklinghausen was the first to describe TSC in 1862, but it was Désiré-
Magloire Bourneville who in the 1880s coined the term “sclérose tubéreuse” after 
discovering sclerotic tubers in postmortem tissues from patients with epilepsy and ID 
(Bourneville 1880; Jay 1999). The neurological phenotypic spectrum of TSC is quite 
variable, ranging from patients with normal intellect and no seizures to those with severe 
ID and medically refractory seizures. The neurological manifestations, however, are the 
most devastating features of the disease and represent the most common causes of 
morbidity and mortality. Seizures are the most common neurological problem occurring 
in 80%–90% of the patients (Curatolo et al. 2008). Intellectual disability and autism 
spectrum phenotypes occur in ∼50% of the patients (Allingham-Hawkins et al. 1999). 
Nonnervous tissue abnormalities and complications include renal angiomyolipomas and 
renal cysts, cardiac rhabdomyomas, retinal hamartomas, enamel pits in permanent teeth, 
arterial aneurysms, and skin abnormalities such as hypomelanotic macules and 
angiofibromas. Neuropathological lesions include subependermal nodules that are 
typically along the walls of the lateral ventricles, giant astrocytomas that might grow into 
the ventricles and cause obstruction and hydrocephalus, and cortical tubers that contain 
abnormally large neurons and glia. Treatment is usually symptomatic, and life 
expectancy is reduced by complications of seizures.  
TSC is caused by mutations in two distinct genes: TSC1 and TSC2. Mutations in TSC1 
cause up to 30% of familial cases and 15% of sporadic causes, whereas mutations in 
TSC2 account for up to 50% of sporadic causes and a high percentage of familial cases 
(Crino et al. 2006; Curatolo et al. 2008).  
Pathophysiology 
The proteins encoded by TSC1 and TSC2, harmartin (TSC1) and tuberin (TSC2), form a 
heterodimeric complex that responds to numerous intracellular signals to regulate (via an 
intermediary called Rheb for “Ras homolog enriched in brain”) the protein kinase mTOR 
(mammalian target of rapamycin) residing in the protein complex mTORC1. TSC1/2 
complex functions as a negative regulator of mTOR (see Fig. 2). Relief from TSC1/2 
repression of mTOR by upstream signaling (e.g., PI3 kinase acting through PDK1 and 
AKT) stimulates cell growth and proliferation, for example, in response to growth factors 
and nutrients. Homozygous silencing mutations of either TSC1 or TSC2 are embryonic 
lethal. Humans born with the disease typically have heterozygous truncating germline 
mutations in either TSC1 or TSC2. It is believed that hamartomas are caused by a “second 
hit” that disables the functional allele (so-called loss of heterozygosity) or otherwise 
impairs the remaining TSC protein, causing uncontrolled cell growth (Orlova and Crino 
2010; Han and Sahin 2011).  
It is not surprising that brain development would be altered by tuber growth and seizures 
during early life (Numis et al. 2011). However, there is a growing appreciation that 
substantial brain dysfunction occurs independently of tumor formation and epilepsy (de 
Vries 2010). This hypothesis received a major boost with the development of rodent 
models of TSC. Heterozygous null mutations of Tsc1 or Tsc2 were both shown to cause 
cognitive and synaptic impairments in the absence of gross neuropathology or seizures 
(von der Brelie et al. 2006; Goorden et al. 2007; Ehninger et al. 2008a; Nie et al. 2010). 
One particularly interesting phenotype reported in the Tsc2+/− mouse is an enhancement 
of late-phase LTP (Ehninger et al. 2008a). Persistent LTP requires synthesis of synaptic 
proteins that might be increased in abundance owing to excess mTOR activity.  
Treatment of Tsc mutant mice with the immunosuppressive drug rapamycin, an mTOR 
inhibitor, ameliorates several phenotypes (Meikle et al. 2008; Ehninger and Silva 2011; 
Tsai and Sahin 2011). Of particular interest are the findings that adult-onset treatment can 
correct the late-phase LTP phenotype as well as learning deficits (Ehninger et al. 2008a). 
This suggests that some synaptic and behavioral phenotypes in TSC, like FXS and Rett 
syndrome (see below), are due to ongoing pathophysiological processes rather than an 
irreversible derailment of development. These pathophysiological changes may be 
corrected with drugs.  
It is noteworthy that the pathogenesis of FXS, AS, and TSC involves regulation of 
synaptic protein abundance and turnover. In FXS this is due to derepression of translation 
of FMRP-target mRNAs; in AS this is due to reduced proteolysis of UBE3a-target 
proteins; and in TSC this is due to derepression of the protein kinase mTOR that 
stimulates mRNA translation. An appealing idea is that overlapping behavioral 
manifestations of these diseases, such as ASD, seizures, and ID, may be related to 
impaired regulation of synaptic protein abundance (Kelleher and Bear 2008). The 
question remains, however, as to the degree to which these disorders share 
pathophysiological changes and respond to similar treatment approaches. Indeed, the 
excessive protein synthesis in the Fmr1-null hippocampus, surprisingly, is not corrected 
by treatment with the mTOR inhibitor rapamycin (Osterweil et al. 2010).  
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SINGLE GENE DISORDERS OF TRANSCRIPTIONAL DYSREGULATION 
Rett Syndrome and MECP2 Disorders  
Clinical Features and Phenotypic Spectrum 
Rett syndrome (RTT) is a neurological disorder that manifests in females during early 
childhood. The disorder was originally described by Andreas Rett (Rett 1966), but it 
became recognized in the medical community when Hagberg and colleagues published a 
description of 35 cases in 1983 (Hagberg et al. 1983). Girls with Rett appear to develop 
normally up to 6–18 mo of age, but head growth typically decelerates, leading to 
microcephaly by the second or third year of life. Patients lose purposeful use of their 
hands and develop stereotypic hand wringing or washing movements. Several autistic 
features including loss of language, social withdrawal, lack of eye-to-eye contact, 
expressionless face, and lack of response to social cues appear after 2 yr of age. 
Cognitive deficits and motor abnormalities including ataxia, apraxia, and rigidity become 
apparent between 3 and 5 yr of age. Autonomic abnormalities such as vasomotor 
disturbances (cold hands and feet) and abnormal breathing patterns (hyperventilation 
alternating with hypopnea during wakefulness) occur in early childhood. Seizures often 
start around 4 yr of age but tend to decrease in severity in adulthood. Similarly, some 
social behaviors improve around 10 yr of age or shortly after (Hagberg 1995; Chahrour 
and Zoghbi 2007; Neul et al. 2010). Additional features include sleep disturbances, teeth 
grinding, screaming fits, anxiety, osteopenia, scoliosis, severe constipation, and cardiac 
abnormalities (including tachycardia, prolonged corrected QT interval, and sinus 
bradycardia). As patients get older, some develop Parkinsonian features (Hagberg 2005). 
Many patients can live into their sixth and seventh decades without evidence of further 
progression of disease.  
The discovery that mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) 
that encodes MeCP2 cause RTT syndrome (Amir et al. 1999) affirmed that this mostly 
(99%) sporadic disorder has a genetic basis and that the majority of the cases (up to 97% 
of classic RTT) are caused by mutations in this gene (Neul et al. 2008). Importantly, the 
discovery of MECP2 as the RTT-causing gene revealed that mutations in this gene cause 
a broad spectrum of neuropsychiatric phenotypes. In females, the phenotypes might range 
from mild learning disabilities to autism, tremors, and anxiety. This is mainly due to 
variation in patterns of X-chromosome inactivation (XCI) (Christodoulou and Ho 1993; 
Zappella et al. 2001; Huppke et al. 2006; Lasalle and Yasui 2009).  
Males with MECP2 mutations have a broad spectrum of phenotypes depending on the 
severity of the mutations. Null alleles cause severe encephalopathy, motor deficits, 
breathing abnormalities, seizures, autonomic dysfunction, and early lethality by 2 yr of 
age. Mutations that partially compromise the function of the protein (such as late 
truncating mutations or hypomorphic missense alleles) lead to a variety of phenotypes 
such as juvenile-onset schizophrenia, bipolar disorders, autism, and Parkinsonian 
features, all typically accompanied by some degree of cognitive deficits and tremors 
(Christodoulou and Ho 1993; Cohen et al. 2002; Klauck et al. 2002). It is remarkable that 
mutations in MECP2 can result in symptoms of almost all neuropsychiatric disorders 
ranging from subtle cognitive deficits to autism, anxiety, ataxia, seizures, Parkinsonism, 
schizophrenia, bipolar, and a plethora of autonomic nervous system abnormalities.  
The finding that duplications and triplications spanning the MECP2 locus in Xq28 cause 
a progressive neurological syndrome highlighted the sensitivity of the nervous tissue to 
precise levels of this protein (Meins et al. 2005; Van Esch et al. 2005). Although the 
duplications and triplications span multiple genes in Xq28, the finding that the minimal 
region of overlap spans MECP2 and the interleukin receptor–associated kinase 1 and that 
the isolated doubling of MeCP2 levels in mice causes most features of the Xq28 
syndrome (Collins et al. 2004; Del Gaudio et al. 2006) pinpointed MECP2 as the 
mediator of the duplication syndrome phenotypes. Males typically have hypotonia and 
developmental delay, manifesting first as autism then progressing to severe motor and 
cognitive impairments, epilepsy, tremors, RTT-like features, and premature lethality 
(Van Esch et al. 2005; Ramocki et al. 2009).  
Female phenotypes include anxiety, depression, broad autism phenotypes, and RTT-like 
symptoms due to variations in patterns of XCI (Ramocki et al. 2009; Ramocki et al. 
2010; Grasshoff et al. 2011). The breadth of the phenotypes associated with either lost or 
increased levels of MeCP2 and the significant overlap in the phenotypes in these two 
disorders raised questions about the mechanisms mediating these disorders, which were 
subsequently clarified through the study of animal models.  
Pathophysiology 
MeCP2 is a nuclear protein that binds to methylated cytosines (Lewis et al. 1992) and is a 
member of a methyl-CpG-binding protein family (Hendrich and Bird 1998). Cell-based 
studies showed that MeCP2 interacts with histone deacetylase–containing complexes and 
represses transcription (Jones et al. 1998; Nan et al. 1998). The findings that gene 
expression changes are subtle in mouse models of RTT, and, surprisingly, several genes 
are down-regulated upon loss of MeCP2 but are increased upon its overexpression, 
suggested that this protein is not a classical transcriptional repressor (Tudor et al. 2002; 
Nuber et al. 2005; Jordan et al. 2007; Chahrour et al. 2008). Indeed, MeCP2 binds to the 
promoter regions of several genes that are repressed upon loss of MeCP2 and are 
activated by its presence, including brain-derived neurotrophic factor (BDNF) and 
several other neuronal genes (Chen et al. 2003; Martinowich et al. 2003; Yasui et al. 
2007; Chahrour et al. 2008). In addition to the gene-specific binding, chromatin-
immunoprecipitation (ChIP) studies revealed that MeCP2 binds widely throughout the 
genome (Yasui et al. 2007; Skene et al. 2010) and is as abundant as one molecule for 
every two nucleosomes (Skene et al. 2010). The findings that MeCP2 and H1 compete 
for DNA binding sites support the hypothesis that MeCP2 might act as an alternative 
linker histone (Ghosh et al. 2010; Skene et al. 2010). However, how such competition 
causes the specific Rett and MeCP2 duplication phenotypes and the root of the very 
specific opposing gene expression changes are not clear at this time. Additional 
molecular and biochemical studies are required to gain better insight into the mechanism 
by which MeCP2 affects gene expression in vivo. While the molecular functions of 
MeCP2 are being elucidated, the neurobiological consequences of either loss or gain of 
this protein have been extensively studied, and such studies have provided important 
insight into the pathogenesis of RTT, MECP2 duplications, and the role of certain 
neurons in mediating specific phenotypes associated with MeCP2 dysfunction.  
MeCP2 is abundant in neurons, and its levels increase postnatally as neurons mature 
(Shahbazian et al. 2002b; Balmer et al. 2003; Kishi and Macklis 2004). Recent studies 
revealed that MeCP2 is also expressed in glia—albeit at lower levels than neurons—and 
that glia lacking MeCP2 fail to support dendritic morphology of either wild-type or 
Mecp2-null neurons (Ballas et al. 2009; Maezawa et al. 2009; Kifayathullah et al. 2010; 
Maezawa and Jin 2010). These studies raised the possibility that some noncell-
autonomous effects from glia contribute to RTT pathogenesis. Although Mecp2-null glia 
might cause or aggravate some of the neuronal phenotypes, several studies, however, 
have shown that loss of MeCP2 specifically from neurons is sufficient to compromise 
function and to cause one or more RTT phenotypes.  
Mice lacking functional MeCP2 reproduce features of RTT (Chen et al. 2001; Guy et al. 
2001; Shahbazian et al. 2002a; Pelka et al. 2006). Despite the devastating neurological 
phenotypes, the brain appears normal, with the exception of microcephaly, decrease in 
dendritic spine density, and dendritic swelling (Belichenko et al. 2009). Mice expressing 
twice the normal levels of MeCP2 reproduce human duplication syndrome features, but 
without much evidence of major pathological changes (Collins et al. 2004). Evidence for 
synaptic abnormalities came from various neurophysiological studies using both RTT and 
duplication models. RTT model studies revealed reduced LTP and impaired synaptic 
plasticity (Asaka et al. 2006; Moretti et al. 2006), whereas doubling MeCP2 caused 
enhanced LTP (Collins et al. 2004). Studies using autaptic preparations from 
hippocampal glutamatergic neurons revealed that neurons lacking MeCP2 have decreased 
excitatory postsynaptic currents (EPSCs), whereas those having excess MeCP2 had 
increased EPSCs, most likely caused by the decrease and increase in the number of 
glutamatergic synapses in these mutants, respectively (Chao et al. 2007). Using human 
induced pluripotent stem cells (iPSCs) from RTT patients, Marchetto et al. (2010) 
showed that neurons derived from RTT-iPSCs were smaller, had fewer synapses, and had 
altered activity-dependent calcium transients and decreased spontaneous postsynaptic 
currents. A reduction in EPSCs and excitatory synaptic strength was also detected using 
cortical slices from Mecp2-null mice (Dani et al. 2005). Additionally, defects in 
inhibitory synaptic transmission were detected in the cortex, hippocampus, and brain 
stem of Mecp2-null mutants (Dani et al. 2005; Medrihan et al. 2008; Zhang et al. 2008). 
Voltage-sensitive dye imaging revealed that area CA1 is hyperexcitable in Mecp2-null 
mice and that this hyperexcitability originates in the CA3 region (Calfa et al. 2011).  
Deletion of MeCP2 from various neuronal types revealed that this protein is critical for 
the functional integrity of a diverse set of neurons. Loss of Mecp2 from forebrain 
glutamatergic neurons causes motor abnormalities, anxiety-like behavior, social 
abnormalities, and impaired learning (Gemelli et al. 2006), whereas a deletion in Sim1 
hypothalamic neurons causes aggression, abnormal stress responses, and hyperphagia 
(Fyffe et al. 2008). Several additional cell-specific deletions caused partial phenotypes of 
RTT (Adachi et al. 2009; Samaco et al. 2009). A more recent study revealed that deletion 
of Mecp2 in GABAergic neurons reproduced most of the features of RTT (including the 
stereotyped behavior and premature lethality) and resulted in reduced GABA signaling 
based on findings of reduced inhibitory quantal size and mIPSCs (Chao et al. 2010). The 
extent of the reduction in glutamate decarboxylase (GAD) expression and GABA 
immunoreactivity in neurons was consistent with the degree of reduction in GABA 
signaling uncovered by the neurophysiological studies. A common theme observed in 
several of the Mecp2 conditional deletions is the cell-autonomous compromise to the 
biosynthetic enzymes critical for the neurotransmitters in the respective neurons (e.g., 
tyrosine hydroxylase in catecholamine neurons and GAD in inhibitory neurons) (Samaco 
et al. 2009; Chao et al. 2010). MeCP2 does bind the promoters of all of the genes 
encoding these enzymes as well as the promoter of various neuropeptides (e.g., Crh, 
Bdnf, and Sst) that are reduced in Mecp2-null mice. In contrast, these neuropeptides are 
increased in MeCP2-overexpressing mice, and there is more MeCP2 binding at their 
respective promoters. Although the way MeCP2 loss or gain regulates key neuronal 
genes is still not fully understood, doubling MeCP2 levels clearly causes disease by a 
gain-of-function (hyperfunction) mechanism.  
The changes in biosynthetic enzymes and neuropeptides suggest that normal Mecp2 
function is critical for activity-dependent gene transcription. This notion is supported by 
the finding that activity leads to phosphorylation of MeCP2 at S421 (Chen et al. 2003; 
Martinowich et al. 2003; Zhou et al. 2006). Although in cell-based assays, 
phosphorylation at S421 appeared to be critical for activity-dependent Bdnf transcription, 
additional in vivo studies are needed to determine the precise effect of S421 
phosphorylation on gene transcription. Mutating S421 to an alanine causes a minor 
phenotype of hyperactivity. In contrast, phosphorylation of MeCP2 at serine 80 seems to 
be decreased by activity, and S80 mutation to alanine causes decrease in locomotor 
activity (Tao et al. 2009).  
Although RTT is a devastating disorder, genetic and pharmacologic studies provide hope 
that the disease is reversible. Silencing of Mecp2 in mice using a lox-Stop-lox cassette 
causes RTT-like features to be reversed if the expression of MeCP2 is induced in adult 
animals (Giacometti et al. 2007; Guy et al. 2007). These results show that the neuronal 
connectivity is intact and the neurons and glia are not permanently damaged from MeCP2 
loss. Tropea et al. (2009) showed that using a fragment of insulin-like growth factor 
(IGF-1) in systemic treatment of MeCP2 mutant mice prolonged their median survival by 
∼5 wk and improved locomotive activity, breathing, and heart rates, and abolished the 
prolonged ocular dominance plasticity seen in Mecp2+/− mice. These findings show that 
the synaptic abnormalities seen in the RTT model are partially reversible using this 
pharmacological approach. Kline et al. (2010) evaluated the synaptic function of the 
nucleus tractus solitarius of Mecp2-null mice and found that the mEPSCs are reduced in 
these mice. Because this synaptic dysfunction was accompanied by decreased BDNF, 
they applied exogenous BDNF to the brain stem preparation and found that it rescued the 
synaptic defects (Kline et al. 2010). Another pathway that is altered in RTT is the 
AKT/mTOR signaling pathway, which is decreased before symptom onset as evidenced 
by significant reductions in levels of phosphorylated ribosomal protein S6 (rpS6) in 
neurons of Mecp2-null mice (Ricciardi et al. 2011). Interestingly, the RTT model shows a 
decrease in AKT/mTOR signaling in contrast with models of TSC and fragile X, in 
which AKT/mTOR activity is increased.  
Although it is too early to determine the ideal therapeutic approach in RTT, several 
findings point to interesting candidates. The reductions of BDNF levels in Mecp2-null 
mice coupled with the amelioration of phenotypes when BDNF is used exogenously or 
genetically (Chang et al. 2006; Kline et al. 2010) raise the possibility that drugs that 
enhance BDNF signaling might rescue RTT phenotypes. The vast number of gene 
expression changes are sure to contribute to the various RTT phenotypes; thus, therapies 
targeting chromatin-remodeling proteins such as histone deacetylase or histone acetylase 
might prove useful. Further studies exploring IGF-1 as a potential therapy are worthy of 
consideration, especially given the reduction in AKT/mTOR activity. Lastly, the finding 
that many RTT phenotypes can be recapitulated by deleting Mecp2 in GABAergic 
neurons raises the possibility that enhancing GABA signaling might rescue several 
phenotypes.  
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CONCLUDING REMARKS 
The study of syndromic autism and disorders associated with cognitive dysfunction has 
had a major impact on the fields of genetics, pediatrics, neurology, psychiatry, and 
neuroscience. Such human studies allowed the identification of the genetic bases of more 
than 100 ASD and ID disorders, permitted genetic counseling and early interventions for 
affected families, and uncovered novel mutational mechanisms. Examples of novel 
mutational mechanisms include genomic disorders involving gains and losses of 
segments of the genomes (Stankiewicz and Lupski 2010), dynamic mutations such as the 
trinucleotide expansions in the fragile X syndrome (Orr and Zoghbi 2007), and genomic 
uniparental disomy or imprinting disorders (Spence et al. 1988; Nicholls et al. 1989). 
From a neurobiological perspective, the gains from studying human patients have been 
enormous. First, we learned that either gains or losses of certain proteins or chromosomal 
segments (e.g., MECP2, SHANK3, and 15q11-13) could cause overlapping phenotypes, 
ID, motor abnormalities, or seizures (Fig. 3). In the case of MeCP2, this happens despite 
opposing molecular and synaptic changes, suggesting that the overlapping features might 
result from failure of homeostatic regulation of synaptic function. This clearly represents 
a challenge for developing therapies that might target more than one type of ID or autism 
spectrum disorder.  
Figure 3. Gain or loss of function of individual genes often yields an overlapping behavioral phenotype 
in humans that includes ASD and ID. The same appears to be true of a physiological process such as 
local synaptic protein synthesis, in which too much or too little can be manifest in similar ways. We 
propose that optimal synaptic function occurs within a limited dynamic range, and the pathophysiology 
at both ends of this range can cause autistic behavior and intellectual disability.  
Disturbances in protein translation at the synapse is an example of a mechanism affecting 
synaptic function and homeostasis, which provides a therapeutic opportunity for more 
than one type of ASD/ID. Loss of FMRP, TSC1/2, PTEN, or Ube3a causes disturbances 
in translational control and impacts protein levels at the synapse. Thus, identifying 
therapies that affect translational control might prove useful for this group of disorders. 
Rapamycin and mGluR5 modulators are emerging as such potential candidates (Aschrafi 
et al. 2005; Dolen et al. 2007; Zhou et al. 2009; Gross et al. 2010; Osterweil et al. 2010; 
Ehninger and Silva 2011). Transcriptional dysregulation is another potential mechanism 
occurring in several disorders caused by loss or gain of function of nuclear factors such 
as MeCP2, CREB-binding protein (Petrij et al. 1995), EP300 (Roelfsema et al. 2005), or 
MEF2C (Le Meur et al. 2010) (Fig. 2). Drugs that target histone deacetylases, histone 
acetylases, or other chromatin-modifying proteins might prove useful in this class of 
disorders.  
Key insight into neurobiology, especially the regulation of synaptic function and 
homeostasis, has been gained from the study of syndromic human disorders and their 
respective animal models. The identification of FMRP and elucidation of its role in 
translational control have uncovered a critical step downstream from the metabotropic 
glutamate receptors (Bear et al. 2004). Genetic studies involving selective deletions of 
Mecp2 in specific neurons permit analysis of the consequences of partial dysfunction of 
such neurons. This is best illustrated by the case of GABAergic neurons, where loss of 
MeCP2 in such neurons uncovered the neuropsychiatric consequences of partial 
reduction in GABA signaling (Chao et al. 2010). The diversity of phenotypes uncovered 
in human patients and the various alleles causing such diverse phenotypes are key for 
dissecting critical domains and residues within a protein and for attributing specific 
neuropsychiatric phenotypes to subtle physiological changes at the synapse.  
Basic research and pathogenesis studies of autism and ID disorders in model organisms 
have been critical in advancing our understanding of several of these disorders. To date, 
many of the potential pathways that can be targeted therapeutically have been defined 
from such fundamental research. The fact that genetic studies have illustrated that some 
of these disorders can be reversible in mice is quite exciting and brings hope that, with 
effective therapies, affected children and young adults might gain skills and functionality. 
The new intense efforts through whole-genome sequencing of samples from 
nonsyndromic ASD and ID cases promise to uncover hundreds of new genes whose 
proteins or RNAs are likely to affect synaptic function. The challenge for neurobiologists 
is to dissect the mechanisms by which these gene products affect synaptic function and to 
identify points of convergence and shared pathways that could affect a group of disorders 
when modified. Children with ASD and ID have taught us more than any model system 
about the exquisite sensitivity of the synapse to subtle molecular perturbation. The 
knowledge we continue to gain from studying human disorders and from pursuing 
fundamental basic research on such disorders will, it is hoped, help develop effective 
therapies for the millions of children affected by these disorders and who have to endure 
their toll for decades.  
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